Technical Analysis for AEZS - AEterna Zentaris Inc.
|Grade||Last Price||% Change||$ Change|
AEZS closed down 5.97 percent on Tuesday, February 21, 2017, on 76 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
Trend Table & Recent Alerts
|Weak or Absent||Down||Down||Flat|
|See historical AEZS trend table...|
|Date||Alert Name||Type||% Chg|
|Feb 21||Fell Below 50 DMA||Bearish||0.00%|
|Feb 21||Stochastic Sell Signal||Bearish||0.00%|
|Feb 21||Expansion Pivot Sell Setup||Bearish Swing Setup||0.00%|
|Feb 16||NR7||Range Contraction||-5.97%|
|Feb 15||Stochastic Reached Overbought||Other||-5.97%|
|Feb 13||Crossed Above 50 DMA||Bullish||-4.55%|
|Feb 9||Bullish Engulfing||Bullish||6.78%|
|Feb 8||Calm After Storm||Range Contraction||12.50%|
|Feb 7||NR7||Range Contraction||10.53%|
|Feb 7||Narrow Range Bar||Range Contraction||10.53%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Aeterna Zentaris Inc. a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for oncology and endocrine therapy primarily in Switzerland, the United States, and Japan. It markets Cetrotide, a luteinizing hormone-releasing hormone antagonist treatment for in vitro fertilization. The companys product pipeline includes AEZS-108, which is in Phase III clinical trial for the treatment of endometrial cancer, as well as in Phase II clinical trial to treat triple-negative breast, ovarian, castration and taxane resistant prostate, and refractory bladder cancers; and AEZS-130, an oral diagnostic test that has completed Phase III clinical trial for adult growth hormone deficiency, as well as in Phase IIA clinical trial for the treatment of cancer-induced cachexia. Its product pipeline also comprise Ozarelix, which is in Phase II clinical trial for the treatment of prostate cancer; Perifosine that is in Phase I/II clinical trials for the treatment of neuroblastoma, glioma, and pediatric solid tumors; and AEZS-112 an oral anticancer agent, which has completed Phase I clinical trial for the treatment of solid tumors and lymphoma. In addition, the companys products in preclinical development consist of AEZS-120, a live recombinant oral tumor vaccine candidate for the treatment of prostate cancer; AEZS-129, 134, and 136 PI3K/Erk inhibitors for oncology; and AEZS-137 and AEZS-125 for oncology. Aeterna Zentaris Inc. was founded in 1990 and is headquartered in Quebec City, Canada.
Is AEZS a Buy, Sell or Hold?
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more AEZS news...
|52 Week High||5.59|
|52 Week Low||2.35|
|200-Day Moving Average||3.46|
|50-Day Moving Average||3.2|
|20-Day Moving Average||2.97|
|10-Day Moving Average||3.15|
|Average True Range||0.22|
|Chandelier Exit (Long, 3 ATRs)||2.79|
|Chandelier Exit (Short, 3 ATRs)||3.01|
|Upper Bollinger Band||3.53|
|Lower Bollinger Band||2.41|
|Percent B (%b)||0.66|